Top

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer

Panelists discuss how recent studies highlight the potential of second-line immunotherapy approaches, including the pembrolizumab-lenvatinib combination and re-challenging with second-line immunotherapy, to improve outcomes in advanced endometrial cancer (EC), with an emphasis on biomarker-driven strategies, careful monitoring for toxicity, and the need for further research to optimize treatment sequencing and patient selection.

Summary for Physicians: Interpretation of Findings From Existing and Upcoming Studies and Case Reports in Advanced EC Dr Birrer to Dr Chan: Response to Lenvatinib and Pembrolizumab Combination Therapy in Pembrolizumab-Pretreated Relapsed EC (K. Mimura et al., Gyn Onc Reports, 2022) Dr Birrer to Dr Naumann: Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma (M.

Morton et al., Obstetrics & Gynecology, 2023) Summary: Both experts interpret findings from existing and upcoming studies that highlight second-line immunotherapy approaches in advanced EC : Both discussions highlight the importance of personalized treatment strategies and biomarker-driven approaches to improve outcomes in patients with advanced EC, while also emphasizing the need for ongoing research to refine these therapies and their safe application..